News >

Frontline Pembrolizumab Improves Survival in HNSCC

Jason M. Broderick @jasoncology
Published: Wednesday, Jul 25, 2018

Dr. Roy Baynes

Roy Baynes, MD, PhD
Pembrolizumab (Keytruda) significantly improved overall survival (OS) compared with the standard frontline regimen of cetuximab (Erbitux) plus platinum chemotherapy and 5-FU in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and a PD-L1 expression level ≥20%, according to findings from the phase III KEYNOTE-048 trial.1

“This interim analysis of the KEYNOTE-048 trial has shown that Keytruda monotherapy has the potential to help patients with head and neck cancer whose tumors express high levels of PD-L1,” Roy Baynes MD, PhD, senior vice president and head of Global Clinical Development, chief medical officer, Merck Research Laboratories, said in a statement.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication